Statistical Methods in Pre- and Clinical Drug Development: Tumour Growth-Inhibition Model Example

Add to your list(s) Download to your calendar using vCal

• Robert Kozarski, AstraZeneca
• Thursday 26 April 2018, 19:15-21:30
• Amgen Ltd, Cambridge Science Park, CB4 0WG.

If you have a question about this talk, please contact Peter Watson.

Modelling of tumour-related outcomes to assess treatment efficacy applies in both pre- and clinical drug development. Stein et al. [2008] proposed a new paradigm to evaluate cancer therapy effectiveness in an early clinical drug development. The model decomposes the observed individual tumour measurements over time into two independent component processes of a constant exponential tumour growth/regrowth and regression (inhibition). The model was also found relevant in modelling pre-clinical in-vivo experimental data, establishing a novel approach in describing the observed tumour volume dynamics beyond a current practice. During the talk, the model pros and cons will be addressed with an example efficacy assessment of the Antibody Drug Conjugate (ADC) cancer therapies on a single study and database meta-analysis level.

This talk is part of the Cambridge Statistics Discussion Group (CSDG) series.

This talk is included in these lists:

• All CMS events
• All Talks (aka the CURE list)
• Amgen Ltd, Cambridge Science Park, CB4 0WG
• BHRU Annual Lecture 2015
• BHRU Annual Lecture 2016
• CMS Events
• Cambridge Cardiovascular Seminar Series
• Cambridge Statistics Discussion Group (CSDG)
• Cardiovascular Epidemiology Unit Special Seminars
• DPMMS Lists
• DPMMS info aggregator
• DPMMS lists
• Department of Public Health and Primary Care
• Public Health talks
• PublicHealth@Cambridge
• School of Physical Sciences
• Statistical Laboratory info aggregator
• bld31
• my_list

Note that ex-directory lists are not shown.